RECRUITINGPhase 4INTERVENTIONAL
The Occurrence of Emergence Agitation in Pediatric Strabismus Surgery
The Effect of Administration of Sugammadex on the Occurrence of Emergence Agitation in Pediatric Strabismus Surgery-prospective Randomized Controlled Trial
About This Trial
The present trial conducted to demonstrate the administration of sugammadex as reversal of neuromuscular blockade agent reduces the incidence of emergence agitation (EA) comparing to neostigmine
Who May Be Eligible (Plain English)
Who May Qualify:
- Patients scheduled elective strabismus surgery aged 4-7 with American Society of Anesthesiologists (ASA) classification 1-3.
Who Should NOT Join This Trial:
- ASA classification 3 or more
- impaired liver function
- impaired kidney function
- myasthenia gravis or other neuromuscular disorders
- history of drug allergy
- cardiovascular disease or arrhythmia
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Patients scheduled elective strabismus surgery aged 4-7 with American Society of Anesthesiologists (ASA) classification 1-3.
Exclusion Criteria:
* ASA classification 3 or more
* impaired liver function
* impaired kidney function
* myasthenia gravis or other neuromuscular disorders
* history of drug allergy
* cardiovascular disease or arrhythmia
Treatments Being Tested
DRUG
Bridion 200 MG in 2 ML Injection
Sugammadex is administered at the end of surgery after assessment of the level of neuromuscular blockade is done. The dosage of each reversal agent is determined with response to TOF or PTC.
DRUG
Pyridostigmine Bromide 5 MG/ML
Pyridostigmine is administered at the end of surgery after assessment of the level of neuromuscular blockade is done. The dosage of each reversal agent is determined with response to TOF.
Locations (1)
Konkuk University Medical Center
Seoul, Seoul-T'ǔkpyǒlshi, South Korea